PXT 3003
- Generic Name
- PXT 3003
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27N3O2
- CAS Number
- 1467047-91-1
- Background
PXT 3003 is in phase 3 clinical trials for the treatment of Charcot-Marie-Tooth disease type 1A in adults.
A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A
- Conditions
- Charcot-Marie-Tooth Type 1A
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Tasly GeneNet Pharmaceuticals Co., Ltd
- Target Recruit Count
- 176
- Registration Number
- NCT05092841
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳Xuanwu Hospital Capital Medical University, Beijing, China
🇨🇳The First Bethune Hospital of Jilin University, Changchun, China
Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
- Conditions
- Charcot-Marie-Tooth Disease, Type IA
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Pharnext S.C.A.
- Target Recruit Count
- 187
- Registration Number
- NCT03023540
- Locations
- 🇧🇪
Departement of Neurology, UZ Leuven, Leuven, Belgium
🇪🇸Servicio de Neurologia, Hospital Universitario i Politécnic La Fe, Valencia, Spain
🇬🇧Department of Neurology, Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
- Conditions
- Charcot-Marie-Tooth Disease Type 1A
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Pharnext S.C.A.
- Target Recruit Count
- 323
- Registration Number
- NCT02579759
- Locations
- 🇺🇸
Department of Neurology, McKnight Brain Institute, Gainesville, Florida, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Department of Neurology, University of Minnesota, Minneapolis, Minnesota, United States
Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
- Conditions
- Genetic DisordersCharcot-Marie-Tooth DiseaseHereditary Neuropathy With Liability to Pressure Palsies
- Interventions
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Pharnext S.C.A.
- Target Recruit Count
- 80
- Registration Number
- NCT01401257
- Locations
- 🇫🇷
Hôpital Roger Salengro, Lille, France
🇫🇷Hôpital La Timone, Marseille, France
🇫🇷Groupe Hospitalier Pitié-Salpétrière, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.